Massive therapy and autologous bone marrow transplantation in very bad prognosis Burkitt's lymphoma. 1985

T Philip, and P Biron, and I Philip, and M Favrot, and G Souillet, and N Philippe, and P Hervé, and E Plouvier, and J L Bernard, and C Raybaud

During 1980-1983, two major advances were made in the treatment of Burkitt's lymphoma (BL): conventional but aggressive chemotherapy raised the overall survival rate from 42% with the SFOP1 protocol, COPAD, to 80% with SFOP protocols LMB 01 and 02; and massive chemotherapy followed by autologous bone-marrow transplantation (ABMT) enabled 40% of relapses to be cured. Ten patients included in the COPAD protocol were treated with massive therapy: seven because of relapse, one because of partial remission after two months' induction therapy and two because of long delay before first complete remission (CR). The therapy used was bischloroethyl nitrosourea, cytosine arabinoside, cyclophosphamide (CPM) and 6-thioguanine (BACT) in nine cases and CPM in one. The response rate was 100%, and disease-free survival was reached in five of ten cases, including four with no evidence of disease for over two years. In nine of ten patients who received ABMT, the bone marrow (BM) was not decontaminated, and BM involvement was found at death prior to day 86 from ABMT in four of five failures. Clinical and cytological analyses led to no firm conclusion about the role, if any, of reinjected BM in this outcome: a liquid-culture monitoring system used in six cases showed BM malignant cells present in the graft in one early relapse and absent in two relapses in which BACT failed; in three long-term survivors, no malignant cell was found in the graft. This first group of ten showed the efficiency of BACT and the necessity of purging BM in at least some cases before ABMT. Of the second group, selected from 43 patients given LMB 01 and 02 protocols, eight were treated by massive therapy and ABMT: one with localized stages I and II disease, four with stage III and three with stage IV. These patients received massive therapy either because of early relapse, progressive disease, partial remission after induction therapy or long delay before CR, or as a consolidation of CR in cases of central nervous system or cerebrospinal fluid involvement. In this group, four of eight are disease-free; three of them had normal BM by in-vitro liquid-culture monitoring; their BM was not decontaminated and they had no BM relapses. In the other five cases, BM was decontaminated by Asta Z in one and by y-29/55 antibody in four.(ABSTRACT TRUNCATED AT 400 WORDS)

UI MeSH Term Description Entries
D008297 Male Males
D009367 Neoplasm Staging Methods which attempt to express in replicable terms the extent of the neoplasm in the patient. Cancer Staging,Staging, Neoplasm,Tumor Staging,TNM Classification,TNM Staging,TNM Staging System,Classification, TNM,Classifications, TNM,Staging System, TNM,Staging Systems, TNM,Staging, Cancer,Staging, TNM,Staging, Tumor,System, TNM Staging,Systems, TNM Staging,TNM Classifications,TNM Staging Systems
D002051 Burkitt Lymphoma A form of undifferentiated malignant LYMPHOMA usually found in central Africa, but also reported in other parts of the world. It is commonly manifested as a large osteolytic lesion in the jaw or as an abdominal mass. B-cell antigens are expressed on the immature cells that make up the tumor in virtually all cases of Burkitt lymphoma. The Epstein-Barr virus (HERPESVIRUS 4, HUMAN) has been isolated from Burkitt lymphoma cases in Africa and it is implicated as the causative agent in these cases; however, most non-African cases are EBV-negative. African Lymphoma,Burkitt Cell Leukemia,Burkitt Tumor,Lymphoma, Burkitt,Burkitt Leukemia,Burkitt's Leukemia,Burkitt's Lymphoma,Burkitt's Tumor,Leukemia, Lymphoblastic, Burkitt-Type,Leukemia, Lymphocytic, L3,Lymphocytic Leukemia, L3,Burkitts Leukemia,Burkitts Lymphoma,Burkitts Tumor,L3 Lymphocytic Leukemia,L3 Lymphocytic Leukemias,Leukemia, Burkitt,Leukemia, Burkitt Cell,Leukemia, Burkitt's,Leukemia, L3 Lymphocytic,Lymphoma, African,Lymphoma, Burkitt's,Tumor, Burkitt,Tumor, Burkitt's
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths

Related Publications

T Philip, and P Biron, and I Philip, and M Favrot, and G Souillet, and N Philippe, and P Hervé, and E Plouvier, and J L Bernard, and C Raybaud
January 1985, [Rinsho ketsueki] The Japanese journal of clinical hematology,
T Philip, and P Biron, and I Philip, and M Favrot, and G Souillet, and N Philippe, and P Hervé, and E Plouvier, and J L Bernard, and C Raybaud
October 1990, Journal of the Medical Association of Thailand = Chotmaihet thangphaet,
T Philip, and P Biron, and I Philip, and M Favrot, and G Souillet, and N Philippe, and P Hervé, and E Plouvier, and J L Bernard, and C Raybaud
August 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
T Philip, and P Biron, and I Philip, and M Favrot, and G Souillet, and N Philippe, and P Hervé, and E Plouvier, and J L Bernard, and C Raybaud
March 1985, Lancet (London, England),
T Philip, and P Biron, and I Philip, and M Favrot, and G Souillet, and N Philippe, and P Hervé, and E Plouvier, and J L Bernard, and C Raybaud
January 1984, Haematologica,
T Philip, and P Biron, and I Philip, and M Favrot, and G Souillet, and N Philippe, and P Hervé, and E Plouvier, and J L Bernard, and C Raybaud
January 1985, IARC scientific publications,
T Philip, and P Biron, and I Philip, and M Favrot, and G Souillet, and N Philippe, and P Hervé, and E Plouvier, and J L Bernard, and C Raybaud
February 1988, [Rinsho ketsueki] The Japanese journal of clinical hematology,
T Philip, and P Biron, and I Philip, and M Favrot, and G Souillet, and N Philippe, and P Hervé, and E Plouvier, and J L Bernard, and C Raybaud
January 1996, Cancer treatment and research,
T Philip, and P Biron, and I Philip, and M Favrot, and G Souillet, and N Philippe, and P Hervé, and E Plouvier, and J L Bernard, and C Raybaud
June 1987, The New England journal of medicine,
T Philip, and P Biron, and I Philip, and M Favrot, and G Souillet, and N Philippe, and P Hervé, and E Plouvier, and J L Bernard, and C Raybaud
January 1990, The American journal of medicine,
Copied contents to your clipboard!